bortezomib, cancer chemotherapy, drug withdrawal, genetic screening, human, letter, onset age, peripheral neuropathy, priority journal, quality of life, risk factor, treatment response, vincristine
dx.doi.org/10.1016/S1470-2045(11)70021-3, hdl.handle.net/1765/23589
The Lancet Oncology
Erasmus MC: University Medical Center Rotterdam

Broyl, A, Jongen, J.L.M, & Sonneveld, P. (2011). Bortezomib-induced peripheral neuropathy: Facts and genes - Authors' reply. The Lancet Oncology, 12(2). doi:10.1016/S1470-2045(11)70021-3